Long-Term Clinical Experience with Vedolizumab in Patients with Mild to Moderate Ulcerative Colitis

Purpose: Binding of mucosal addressin cell adhesion molecule 1 (MAd-CAM-1) by α4β7 mediates migration of leukocytes into gastrointestinal mucosa and associated lymphoid tissue. Vedolizumab (VDZ) (previous versions MLN0002, MLN02, LDP-02) is an investigational gut-selective biologic that antagonizes α4β7. We describe the long-term clinical experience of 53 patients with mild to moderate ulcerative colitis (UC) who received VDZ for up to 2.5...